CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing new therapies for different breast cancer subtypes using patient-derived xenografts. By combining p38 MAPK inhibitors with chemotherapy, the aim is to improve treatment outcomes for patients with breast cancer.
Breast tumors are classified by several grading systems and divided into four main molecular subtypes:
Luminal A, Luminal B, Triple negative/basal-like and HER2+.
Since luminal A tumors tend to be ER+, their treatment often includes hormonal therapy. HER2+ tumors can be treated with Trastuzumab, an anti-Her2 receptor antibody.
Hormonal therapies or Trastuzumab cannot be used for triple negative tumors, which are ER- and HER2-, and these are usually treated with a combination of surgery, radiothe…
FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
